SHORT COMMUNICATION

Iranian Biomedical Journal 21(2): 126-128 March 2017

The First Report of a 290-bp Deletion in β-Globin Gene in the South of Iran

Mohammad Hamid¹,², Ladan Dawoody Nejad¹, Gholamreza Shariati*²,³, Hamid Galehdari ³, Alihossein Saberi²,³ and Marziye Mohammadi-Anaei²

¹Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran; ²Narges Medical Genetics and Prenatal Diagnosis Laboratory, No. 18, East Mihan Ave., Kianpars, Ahvaz, Iran; ³Department of Medical Genetic, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Received 14 December 2015; revised 6 February 2016; accepted 10 February 2016

ABSTRACT

Background: β-thalassemia is one of the most widespread diseases in the world, including Iran. In this study, we reported, for the first time, a 290-bp β-globin gene deletion in the south of Iran. Methods: Four individuals from three unrelated families with Arabic ethnic background were studied in Khuzestan Province. Red blood cell indices and hemoglobin analysis were carried out according to the standard methods. Genomic DNA was obtained from peripheral blood cells by salting out procedures. β-globin gene amplification, multiplex ligation-dependent probe amplification (MLPA), and DNA sequencing were performed. Results: The PCR followed by sequencing and MLPA test of the β-globin gene confirmed the presence of a 290-bp deletion in the heterozygous form, along with -88C>A mutation. All the individuals had elevated hemoglobin A₂ and normal fetal hemoglobin levels. Conclusions: This mutation causes β+thalassemia and can be highly useful for prenatal diagnosis in compound heterozygous condition with different β-globin gene mutations. DOI: 10.18869/acadpub.ibj.21.2.126

Keywords: β-thalassemia, β-globin gene mutation, Iran, Multiplex ligation-dependent probe amplification

INTRODUCTION

β-thalassemia is one of the most frequent genetic disorders in Iran with a great mutational diversity. More than 280 mutations have been identified in association with β-thalassemia in the country. Mutations are mostly single base substitutions, and in some cases, they may cause deletions or insertions of different regions in a gene²,³. β-globin gene deletions, especially those in promoter regions, are usually associated with the high levels of hemoglobin A₂ (HbA₂) in heterozygous individuals. In addition, the high levels of fetal hemoglobin (HbF) are detected because of δβ-globin gene deletions. However, large deletions of δβ- and γ-globin genes are observed among some carriers with normal levels of HbF. Since most deletions may be missed by DNA sequencing, the identification of deletions in β-globin gene by other means is of great important³,⁴. In the current study, we detected a 290-bp deletion in four individuals from three unrelated families with Arabic ethnic background in Khuzestan Province, south of Iran.

MATERIALS AND METHODS

The present investigation is a part of a national program for the prevention of thalassemia. In total, four individuals who referred to the Narges Prenatal Diagnostics and Medical Genetics Laboratory (Ahvaz, Iran) during three years participated in this study. The analysis of red blood cell indices and Hb analysis were
carried out according to the standard methods. Following a written informed consent from the subjects, some molecular studies were conducted on the genomic DNA isolated from peripheral blood cells using a salting out procedure. To identify α-thalassemia genotype, the common Mediterranean α-globin gene deletions were investigated by Gap-PCR as described elsewhere. β-globin gene was amplified and directly sequenced by the chain termination method on the ABI PRISM 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

For detection of deletions, multiplex ligation-dependent probe amplification (MLPA) assay was performed using the SALSA MLPA kit P102 HBB (MRC-Holland, Amsterdam, Netherlands). Then amplified fragments were separated by capillary electrophoresis on the ABI PRISM 3130 Genetic Analyzer (Applied Biosystems, Foster city, CA, USA) and analyzed by GeneMarker software v.1.6 (Soft Genetics, State College, PA, USA).

RESULTS

This study reported, for the first time, a 290-bp deletion (c.-176_92+25del) in β-globin gene in four individuals from three unrelated families with Arabic ethnic background in Khuzestan Province. All the individuals had elevated HbA2 and normal HbF levels. One of the individuals, offspring of K.B., was a 5-year-old girl, who inherited both defects (290-bp deletion/-88 C>A mutation) from her parents. Physical examination of the patient indicated pallor, slight hepatosplenomegaly. The hematological and molecular data of the studied subjects are summarized in Table 1.

The 290-bp deletion was characterized by DNA sequencing and MLPA test. The mutation removed the region between positions -125 and +78 relative to the β-globin gene mRNA cap site. The MLPA results confirmed the deletion by probes ranging from prob 21 (Promoter) to prob 1 (HBB intron 1) (Fig. 1). Generally, no mutation or deletion was found in the α-globin genes of the studied individuals.

DISCUSSION

The 290-bp deletion was first observed in a Turkish patient and later in many other patients. In the present investigation, we reported, for the first time, a 290-bp deletion along with -88C>A mutation in the south of Iran.

The mutation removed the region between positions -125 and +78 relative to the β-globin gene mRNA cap site. According to a previous study, a -88C>A mutation allows the β-locus control region to interact with the promoters of δ- and γ-globin genes by competition between fetal and adult globin genes, which result in HbA2 and HbF levels. However, our samples with a 290-bp deletion were just associated with the increased levels of HbA2 and normal HbF. Some of the deleted elements in positions -125 and +78 are the CAC (−90), CAAT (−70) and TATA (−30) boxes. The absence of these elements is led to increased HbA2 levels without any effect on γ-globin genes, which is in contrast to the previous reports.

The detection of this β-thalassemia deletion in the promoter region, which is an available place for transcription factors, can be highly useful for prenatal diagnosis as the consanguineous and ethnic marriages in families compatible the control of the disease.

Table 1. The hematological and molecular data of the studied subjects

<table>
<thead>
<tr>
<th>Age (year)</th>
<th>S.M.</th>
<th>M.M.</th>
<th>K.B.</th>
<th>Offspring of K.B.</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>24</td>
<td>48</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>F</td>
</tr>
<tr>
<td>Hb (g/dl)</td>
<td>10.9</td>
<td>11.5</td>
<td>12.5</td>
<td>6.4</td>
</tr>
<tr>
<td>RBC (10^12/L)</td>
<td>5.19</td>
<td>6.33</td>
<td>5.99</td>
<td>3.58</td>
</tr>
<tr>
<td>MCV(fl)</td>
<td>64.5</td>
<td>64.8</td>
<td>66.8</td>
<td>59.3</td>
</tr>
<tr>
<td>MCH(pg)</td>
<td>21</td>
<td>21.8</td>
<td>20.9</td>
<td>17.9</td>
</tr>
<tr>
<td>MCHC(%)</td>
<td>32.5</td>
<td>-</td>
<td>31.3</td>
<td>30.2</td>
</tr>
<tr>
<td>HbA(%)</td>
<td>94.6</td>
<td>92.9</td>
<td>-</td>
<td>94.8</td>
</tr>
<tr>
<td>HbF(%)</td>
<td>0.4</td>
<td>0.6</td>
<td>-</td>
<td>0.0</td>
</tr>
<tr>
<td>HbA2(%)</td>
<td>5</td>
<td>6.5</td>
<td>-</td>
<td>5.2</td>
</tr>
<tr>
<td>β-genotype</td>
<td>290-bp deletion/N</td>
<td>290-bp deletion/N</td>
<td>290-bp deletion/N</td>
<td>290-bp deletion/-88 C&gt;A</td>
</tr>
<tr>
<td>α-genotype</td>
<td>aa/aa</td>
<td>aa/aa</td>
<td>aa/aa</td>
<td>aa/aa</td>
</tr>
<tr>
<td>Origin</td>
<td>Arab</td>
<td>Arab</td>
<td>Arab</td>
<td></td>
</tr>
</tbody>
</table>

F, female; M, male; N, normal
Identification of 290-bp Deletion on the β-Globin Gene

Hamid et al.


CONFLICT OF INTEREST. None declared.

REFERENCES


9. Diaz-Chico JC, Yang KG, Kutlar A, Reese AL, Aksoy M, Huisman TH. An approximately 300 bp deletion involving part of the 5’ beta-globin gene region is observed in members of a Turkish family with betathalassemia. Blood journal 1987; 70(2): 583-386.


Fig. 1. The chromatogram and histogram of multiplex ligation-dependent probe amplification (MLPA) dosage showing a 290-bp deletion on β-globin gene. (a) The sequence of a 290-bp deletion presenting in heterozygosity; (b) The histogram of MLPA showing a 290-bp deletion.